The mission of Triad Sickle Cell Anemia Foundation is to provide services which improve the quality of life for sickle cell disease patients and their families; provide education and counseling services to health professionals and the community at large; and promote research associated with improved medical and psychosocial treatment of patients. This mission has been enhanced through the cooperative contractual agreement with Duke University Medical Sickle Cell Center. Community based centers, as Triad, are the direct linkage and service provider for sickle cell patients, while Comprehensive Sickle Cell Centers avail clinical expertise, improved methods of care and consultations to community centers and local medical providers. Specific objectives include: Assess patient and family needs annually with semi-annual follow-up; coordinate services to assist families in accessing health and psychosocial resources which enhance patient wellness, growth, development, and independence; promote patient education and resource utilization through sickle cell clinics and individual/group education and counseling sessions; reduce infant mortality/morbidity through aggressive follow-up of newborns with sickle cell disease; increase awareness of sickle cell disease through formal/informal education of lay and professional audiences and by designing and utilizing specific marketing tools; provide genetic counseling for person and parents of individuals with abnormal hemoglobins -- with special emphasis on parents of newborns who have sickle cell trait or disease; promote the independence and self-esteem building of children of ages 6 to 16 years through the Annual Sickle Cell Summer Enrichment Camp; promote patient advocacy through support group activities; and provide resources/opportunities for unemployed/underemployed patients to acquire career training and/or suitable employment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL028391-14
Application #
5213399
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
1996
Total Cost
Indirect Cost
Ariens, Robert A S; Lai, Thung-Shenq; Weisel, John W et al. (2002) Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100:743-54
Ware, Russell E; Eggleston, Barry; Redding-Lallinger, Rupa et al. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99:10-4
Thompson Jr, Robert J; Gustafson, Kathryn E; Bonner, Melanie J et al. (2002) Neurocognitive development of young children with sickle cell disease through three years of age. J Pediatr Psychol 27:235-44
Slaughter, T F; Sreeram, G; Sharma, A D et al. (2001) Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 12:85-93
Lai, T S; Hausladen, A; Slaughter, T F et al. (2001) Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40:4904-10
Ataga, K I; Orringer, E P (2000) Renal abnormalities in sickle cell disease. Am J Hematol 63:205-11
Ataga, K I; Orringer, E P (2000) Bone marrow necrosis in sickle cell disease: a description of three cases and a review of the literature. Am J Med Sci 320:342-7
Kinney, T R; Helms, R W; O'Branski, E E et al. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94:1550-4
Lai, T S; Slaughter, T F; Peoples, K A et al. (1999) Site-directed mutagenesis of the calcium-binding site of blood coagulation factor XIIIa. J Biol Chem 274:24953-8
Slentz-Kesler, K A; Hale, L P; Kaufman, R E (1998) Identification and characterization of K12 (SECTM1), a novel human gene that encodes a Golgi-associated protein with transmembrane and secreted isoforms. Genomics 47:327-40

Showing the most recent 10 out of 78 publications